Cycle frequency: Every four weeks Total number of cycles: 6-8



Similar documents
Schedule: Drug Dose iv/infusion/oral q Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2

Schedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8

Cycle frequency: Every three weeks Total number of cycles: 3 or 4

West of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021)

NORDIC. Indication Mantle cell lymphoma (for patients suitable for subsequent chemotherapy with haematopoietic stem cell rescue)

Lung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC)

Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer

Fludarabine based chemotherapy [Fludarabine, FC, FCR, FMD]

Regimen : Fludarabine Cyclophosphamide Rituximab (FCR-oral)

Severe rheumatoid arthritis (a disease that causes inflammation of the joints),where MabThera is given intravenously together with methotrexate.

In non-hodgkin s lymphoma, MabThera is used to treat two types of the disease, both of which affect B-lymphocytes:

BCCA Protocol Summary for Advanced Therapy for Relapsed Testicular Germ Cell Cancer Using PACLitaxel, Ifosfamide and CISplatin (TIP)

Network Chemotherapy Regimens

West of Scotland Cancer Network Systemic Anti-Cancer Therapy Protocol

Thames Valley Chemotherapy Regimens

PREMEDICATIONS: Agent(s) Dose Route Schedule

Docetaxel, Carboplatin and Trastuzumab (TCH i.e. Taxotere Carboplatin, Herceptin ) for Early Breast Cancer

Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail

Breast Pathway Group FEC(100)-Docetaxel: Fluorouracil / Epirubicin / Cyclophosphamide followed by Docetaxel in Early Breast Cancer

Regimen: Gemcitabine & Carboplatin for NSCLC

London Cancer. Mesothelioma Lung Protocols

Thames Valley Cancer Network. Network Chemotherapy Protocols Breast Cancer

Regimen: Fluorouracil, Epirubicin and Cyclophosphamide + Docetaxel (FEC/T) for Early Breast Cancer

Prior Authorization Guideline

This 2-part article will discuss 9 anticancer. Commonly Used Chemotherapy Drugs Part 1. M e d i c a t i o n s. Clinician s Brief.

rituximab 1400mg solution for subcutaneous injection (Mabthera ) SMC No. (975/14) Roche Products Limited

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)

Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY

Chapter 7: Lung Cancer

AC-Docetaxel: Doxorubicin / Cyclophosphamide followed by Docetaxel in Breast Cancer

BCCA Protocol Summary for Central Nervous System Prophylaxis with High Dose Methotrexate, CHOP and rituximab in Diffuse Large B-cell Lymphoma

Case Report in Oncology Pharmacy. Therapy and supportive care of a high-grade non-hodgkin s lymphoma

Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

Cyclophosphamide/Rabbit Anti-Thymocyte Globulin for Allograft

CHEMOTHERAPY PROTOCOLS V10.1

SMALL CELL LUNG CANCER

Salvage Chemotherapy with Dexamethasone, Etoposide, Ifosfamide and Cisplatin (DVIP) for Relapsing and Refractory Non-Hodgkin s Lymphoma

Hydration Protocol for Cisplatin Chemotherapy

5-Fluorouracil & Radiotherapy for Adjuvant Oesophageal or Gastric Cancer (Modified Macdonald Protocol)

BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA)

David Loew, LCL MabThera

DE Tsai 1, HCF Moore 1, CL Hardy 2, DL Porter 1, EY Loh 1, DJ Vaughn 1, S Luger 1, SJ Schuster 1 and EA Stadtmauer 1

Treatment of low-grade non-hodgkin lymphoma

Adverse Effects of Chemotherapy

Regimen : EOX (Epirubicin, Oxaliplatin and Capecitabine (Xeloda ))

Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC)

Lymphoma: The Roleof Nurses in the Treatment Process

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla

CHOP Chemotherapy Regimen for Lymphoma Information for Patients

DIFFUSE LARGE B-CELL LYMPHOMA

Cytotoxic and Biotherapies Credentialing Programme Module 5

BREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine

Breast Cancer. Breast Cancer Page 1

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group

WM: Managing the Side Effects of Treatment

Treating myeloma. Dr Rachel Hall Royal Bournemouth Hospital

CVP Chemotherapy Regimen for Lymphoma Information for Patients

3 Regime Prescription Practical considerations 4 Pre-infusion Assessment 4 Administration. 5 Checklist. 5 Administering the infusion

Activity of pemetrexed in thoracic malignancies

Prior Authorization Guideline

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma

Aggressive lymphomas. Michael Crump Princess Margaret Hospital

Managing Lymphoma. Professor Clare Knottenbelt BVSc MSc DSAM MRCVS

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need?

IV Thiotepa/Busulfan/Fludarabine/ATG for Allograft

Basics of Systemic Anticancer Therapy Prescribing and Verification

Shared Care Guideline for the use of Leflunomide for Rheumatoid Arthritis

Michael Crump MD. Lymphoma Site Leader Princess Margaret Hospital University of Toronto

Frequency of NHL Subtypes in Adults

autoimmune disease New biotherapy drugs and older chemotherapy agents may improve quality of life in patients with autoimmune diseases.

J Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION

Chemotherapy for lung cancer

For the Patient: CHOP-R Other names: LYCHOP-R

Update in Hematology Oncology Targeted Therapies. Mark Holguin

Vincristine by short infusion Doxorubicin by injection Cyclophosphamide by injection Rituximab by an infusion over between 60 minutes to a few hours

Cytotoxic and Biotherapies Credentialing Programme Module 2

Background Information Myeloma

Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment

Guidelines for the use of Rituximab in Non-Hodgkin s Lymphoma QEII Health Sciences Centre

ONCOLOGY LETTERS 8: , 2014

New Treatment Options for Breast Cancer

This regimen has low emetogenic potential refer to local protocol None required routinely. Baseline results valid for 7 days. Results valid for 72 hrs

Transcription:

Fludarabine Low Grade non-hodgkin s Lymphoma and CLL Fludarabine 25mg/m 2 oral Days 1-5 Cycle frequency: Every four weeks Total number of cycles: 6-8 Anti-emetic group Low Prophylactic co-trimoxazole and valaciclovir Round Fludarabine to the nearest 10mg Toxicities: Myelosuppression and risk of neutropenic sepsis or haemorrhage, nausea, mucositis, amenorrhoea, pneumonitis, carcinogenesis, infertility, hair thinning, fluid retention Symptomatic treatment of side effects: Mouth care Pre-treatment U &E s, LFTs, creatinine, urate CXR CXR After every two cycles Review in the Medical Oncology Clinic 4 weeks after last cycle Reference: Foran et al, 1999. J. Clin. Oncol., 17; pages 546-553 3 rd Edition 88

Indication: CVP Low Grade non-hodgkin s lymphoma and CLL Cyclophosphamide 750mg/m 2 iv Day 1 Vincristine 1.4mg/m 2 (max 2mg) iv Day 1 Prednisolone 100mg oral Days 1-5 Cycle frequency: Every three weeks Total number of cycles: 6 Anti-emetic group Low Do not cap BSA vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, constipation, haemorrhagic cystitis, nephrotoxicity, diarrhoea, carcinogenesis, infertility, urate, creatinine clearance After every two cycles Reference: Rosenberg SA, 1985. J. Clin. Oncol., 3; pages 299-310 3 rd Edition 89

Indication: CVP-R Low Grade non-hodgkin s lymphoma and CLL Cyclophosphamide 750mg/m 2 iv Day 1 Vincristine 1.4mg/m 2 (max 2mg) iv Day 1 Prednisolone 100mg oral Days 1-5 Rituximab 375mg/m 2 500mls N. Saline Day 1 as per datasheet Cycle frequency: Every three weeks Total number of cycles: 6-8 Anti-emetic group Low Do not cap BSA Pre-med Rituximab paracetamol, chlorpheniramine, dexamethasone Rituximab Rapid Infusion guidelines apply vomiting, mucositis, alopecia, amenorrhoea, peripheral neuropathy, constipation, haemorrhagic cystitis, nephrotoxicity, diarrhoea, carcinogenesis, infertility, sensitivity reaction to rituximab, urate, creatinine clearance After every two cycles Reference: Marcus et al, 2005. Blood, 105; pages 1417-1423 3 rd Edition 90

FMD Low Grade non-hodgkin s Lymphoma Fludarabine 25mg/m 2 iv/30mins Days 1-3 Mitozantrone 10mg/m 2 100ml N. Saline/10mins Day 1 Dexamethasone 20mg oral Days 1-5 Cycle frequency: Every four weeks Total number of cycles: 6 Anti-emetic group High on Day 1 Delay if neutrophils - < 1.0 x 10 9 /L or platelets < 100 x 10 9 /L Ensure adequate renal function Prophylactic co-trimoxazole and valaciclovir vomiting, mucositis, alopecia, cardiotoxicity, amenorrhoea, peripheral neuropathy, constipation, encephalopathy, haemorrhagic cystitis, nephrotoxicity, diarrhoea, carcinogenesis, infertility, urate, creatinine clearance After three cycles Reference: Crawley et al, 2000. Ann. Oncol., 11; pages 861-865 3 rd Edition 91

CHOP Non-Hodgkin s Lymphoma Drug Dose in/infusion/oral q Cyclophosphamide 750mg/m 2 iv Day 1 Doxorubicin 50mg/m 2 iv Day 1 Vincristine 1.4mg/m 2 (max 2mg) iv Day 1 Prednisolone 100mg oral Days 2-5 Cycle frequency: Every two to three weeks Total number of cycles: 6-8 Anti-emetic group Moderately high Delay if neutrophils <1.0 x 10 9 /L or platelets < 100 x 10 9 /L Ensure adequate renal function and liver function Do not cap BSA vomiting, mucositis, alopecia, cardiotoxicity, amenorrhoea, peripheral neuropathy, constipation, haemorrhagic cystitis, diarrhoea, carcinogenesis, infertility, urate, creatinine clearance After every two cycles Reference: Coiffier et al, 1991. J. Clin. Oncol., 9; pages 211-219 3 rd Edition 92

CHOP-R Non-Hodgkin s Lymphoma (B-cell) Cyclophosphamide 750mg/m 2 iv Day 1 Doxorubicin 50mg/m 2 iv Day 1 Vincristine 1.4mg/m 2 (max 2mg) iv Day 1 Prednisolone 100mg oral Days 2-5 Rituximab 375mg/m 2 500mls N. Saline Day 1 as per datasheet Cycle frequency: Every two to three weeks Total number of cycles: 6-8 Anti-emetic group Moderately High Delay if neutrophils <1.0 x 10 9 /L or platelets < 100 x 10 9 /L Ensure adequate renal function and liver function Rituximab should be given pre-chop on cycle 1, subsequent cycles the order does not matter Pre-med Rituximab paracetamol, chlorpheniramine, dexamethasone Rituximab Rapid Infusion guidelines apply Do not cap BSA vomiting, mucositis, alopecia, cardiotoxicity, amenorrhoea, peripheral neuropathy, constipation, haemorrhagic cystitis, diarrhoea, carcinogenesis, infertility, sensitivity reaction to rituximab Symptomatic treatment of side effects: Mouth care encourage oral fluids, urate, creatinine clearance After every two cycles Reference: Coiffier et al, 2002. N. Engl. J. Med., 346; pages 235-242 3 rd Edition 93

CHOP-R (with Intrathecal Methotrexate) Non-Hodgkin s Lymphoma Cyclophosphamide 750mg/m 2 iv Day 1 Doxorubicin 50mg/m 2 iv Day 1 Vincristine 1.4mg/m 2 (max 2mg) iv Day 1 Prednisolone 100mg oral Days 2-5 Rituximab 375mg/m 2 500mls N. Saline Day 1 Methotrexate 12.5mg I/T Day 1 Cycle frequency: Every two to three weeks Total number of cycles: 6-8 Anti-emetic group Moderately High Delay if neutrophils <1.0 x 10 9 /L or platelets < 100 x 10 9 /L Ensure adequate renal function and liver function Intrathecal methotrexate to be given in accordance with local policy Rituximab should be given pre-chop on cycle 1, subsequent cycles the order does not matter Pre-med Rituximab paracetamol, chlorpheniramine, dexamethasone Rituximab Rapid Infusion guidelines apply Do not cap BSA vomiting, mucositis, alopecia, cardiotoxicity, amenorrhoea, peripheral neuropathy, constipation, haemorrhagic cystitis, diarrhoea, carcinogenesis, infertility, sensitivity reaction to rituximab, post-lumbar puncture headache, meningeal irritation Symptomatic treatment of side effects: Mouth care encourage oral fluids, urate, creatinine clearance Reference: Coiffier et al, 2002. N. Engl. J. Med., 346; pages 235-242 3 rd Edition 94

PIE (Cisplatin/Ifosfamide/Etoposide) Lymphoma - Recurrent Etoposide 133mg/m 2 500mls N. Saline/2hr Days 1-3 Ifosfamide 2,000mg/m 2 1L N. Saline/4 hrs Days 1-3 Cisplatin 33mg/m 2 1L N. Saline/2hrs Days 1-3 Cycle frequency: Every three weeks Total number of cycles: 4 Anti-emetic group High Ensure adequate renal function Pre & post hydration, mannitol, potassium & magnesium Mesna dose guidelines vomiting, mucositis, alopecia, cardiotoxicity, peripheral neuropathy, nephrotoxicity, ototoxicity, constipation, haemorrhagic cystitis, diarrhoea, carcinogenesis, infertility U & E s, LFTs, Mg 2+, Ca 2+, creatinine, urate, creatinine clearance U & E s, LFTs, Mg 2+, Ca 2+, creatinine After each cycle Reference: Gupta, 1996 3 rd Edition 95

R-ICE (Carboplatin/Ifosfamide/Etoposide) Lymphoma - Recurrent Rituximab 375mg/m 2 500mls N. Saline Day 1 Etoposide 100mg/m 2 500mls N. Saline/2hr Days 1-3 Ifosfamide 5,000mg/m 2 1L N. Saline/24 hrs Day 2 Carboplatin AUC 5 500mls 5% dextrose/1hrs Day 2 Cycle frequency: Every 2 weeks Total number of cycles: 3 Anti-emetic group High Ensure adequate renal function, hydration Mesna dose guidelines apply Prophylactic pegylated G-CSF on day 5 Pre-med Rituximab paracetamol, chlorpheniramine, dexamethasone Rituximab Rapid Infusion guidelines apply vomiting, mucositis, alopecia, cardiotoxicity, peripheral neuropathy, nephrotoxicity, ototoxicity, constipation, haemorrhagic cystitis, diarrhoea, carcinogenesis, infertility U & E s, LFTs, Mg 2+, Ca 2+, creatinine, urate, creatinine clearance U & E s, LFTs, Mg 2+, Ca 2+, creatinine After each cycle Reference: Kewalramani et al, 2004. Blood, 103; pages 3684-3688 3 rd Edition 96

VAPEC-B Non-Hodgkin s Lymphoma Cyclophosphamide 350mg/m 2 iv Day 1 Doxorubicin 35mg/m 2 iv Days 1 & 15 Vincristine 1.4mg/m 2 iv (max 2mg) Days 8 & 22 Bleomycin 10,000iu/m 2 200mls N. Saline/30mins Day 8 Etoposide 100mg/m 2 oral Days 15-19 Prednisolone 50mg/m 2 daily Weeks 1-6 Prednisolone 25mg/m 2 daily Weeks 7-12 Cycle frequency: Every four weeks Total number of cycles: 3 Dose modification: Discuss with Consultant Anti-emetic group Moderately high on days 1 and 15 Ensure adequate renal function and liver function Prophylactic PPI and co-trimoxazole Round Etoposide dose to the nearest 50mg vomiting, mucositis, alopecia, cardiotoxicity, amenorrhoea, peripheral neuropathy, constipation, haemorrhagic cystitis, diarrhoea, carcinogenesis, infertility, urate, creatinine clearance After every cycle Review in the Medical Oncology Clinic 4 weeks after last cycle Reference: Radford et al, 1994. Ann. Oncol., 5; pages 147-155 3 rd Edition 97

Indication: Rituximab (Mabthera) Non Hodgkin s Lymphoma Rituximab 375mg/m 2 500mls N. Saline Day 1 as per datasheet Cycle frequency: Every week Total number of cycles: 4 (8) Dose modification: Discuss with Consultant Anti-emetic group Low Pre-med Rituximab paracetamol, chlorpheniramine, dexamethasone Rituximab Rapid Infusion guidelines apply Toxicities: Myelosuppression and risk of neutropenic sepsis or haemorrhage, nausea, hyper-sensitivity reaction, carcinogenesis, infertility, allergic-like reaction, bronchospasm, hypotension, cardiotoxicity, chills/fevers, rigors Symptomatic treatment of side effects: Supportive therapy, urate Reference: Davis et al, 1999. J. Clin. Oncol., 17; pages 1851-1857 3 rd Edition 98

ESHAP Recurrent lymphoma and Hodgkin s disease Cisplatin 25mg/m 2 iv continuous infusion Days 1-4 Etoposide 40mg/m 2 500mls N. Saline/1hr Days 1-4 Methylprednisolone 500mg 100ml N. Saline/30mins Days 1-5 Cytarabine 2000mg/m 2 500mls N. Saline/2hrs Day 5 Cycle frequency: Every three-four weeks Total number of cycles: 6 Anti-emetic group High Delay if neutrophils < 1.5 x 10 9 /L or platelets < 100 x 10 9 /L Ensure adequate renal function Pre & post hydration, mannitol, potassium & magnesium Double/triple lumen Hickman line required Pre-mild eye drops post cytarabine vomiting, mucositis, conjunctivitis, alopecia, peripheral neuropathy, nephrotoxicity, ototoxicity, diarrhoea, red skin, carcinogenesis, infertility, ESR U & E s, LFTs, Mg 2+, Ca 2+, creatinine, urate, creatinine clearance inc. CT scans, ESR U & E s, LFTs, Mg 2+, Ca 2+, creatinine CXR Re-assess prior to third cycle Reference: Velasquez et al, 1994. J. Clin. Oncol., 12; pages 1169-1176 3 rd Edition 99